Epigenetic control of malignant melanoma

Add to your list(s) Download to your calendar using vCal

• Emily Bernstein, Icahn School of Medicine at Mount Sinai
• Thursday 21 February 2019, 13:00-14:00
• CRUK CI Lecture Theatre.

If you have a question about this talk, please contact Kate Davenport.

Cutaneous melanoma is a highly aggressive skin cancer and one of the most challenging cancers in its therapeutic management. Emerging studies demonstrate that cancer is a result of a concerted action of genetic and epigenetic alterations. Our understanding of the ‘epigenetic landscape’ of melanoma remains poorly understood. We have shown a critical role for histone variants of the H2A family in regulating melanoma pathogenesis. For example, macroH2A acts as a barrier to melanoma growth and metastasis (Kapoor et al., Nature 2010), and H2A .Z.2 promotes melanoma growth by positively regulating transcription of E2F target genes (Vardabasso et al., Molecular Cell 2015). Studies will be presented of our ongoing efforts to identify key epigenetic players in melanoma progression and drug resistance, and to decipher the melanoma epigenome by comparing normal melanocytes with malignant melanoma cells.

This talk is part of the Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer series.

This talk is included in these lists:

• All Talks (aka the CURE list)
• Biology
• CCC talks for website
• CRUK CI Lecture Theatre
• CRUK CI Seminars
• Cancer Research UK Cambridge Institute (CRUK CI) Seminars in Cancer
• Graduate-Seminars
• Liam
• Life Sciences
• Life Sciences
• ME Seminar
• PMRFPS's
• cri
• my_list
• other talks
• se393's list
• sfm36

Note that ex-directory lists are not shown.